Inhibition of catechol-0-methyltransferase (COMT) activity by Tolcapone was shown to result in increase of the striatal DA extracellular content in unrestrained rats pretreated with L-3,4-dihydroxyphenilalanine combined with Carbidopa, the decarboxylation inhibiting agent. Tolcapone enhanced the increase of the DA level in the rat striatal dialysates produced by treatment of these animals with specific DA re-uptake blocker GBR 12909. The latter elicits stereotype behaviour in rats that is substantially enhanced by tolcapone. The DA turnover rate in the striatum was decreased by the GBR 12909. The data obtained suggest that the DA transporter of neuronal membrane plays a major role in the neurochemical homeostasis at synaptic level.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The dopamine transporter inhibition using GBR 12909 as a novel pharmacological tool to assess bipolar disorder-like neurobehavioral phenotypes in zebrafish.
Behav Brain Res
February 2025
Laboratory of Experimental Neuropsychobiology, Department of Biochemistry and Molecular Biology, Natural and Exact Sciences Center, Federal University of Santa Maria, 1000 Roraima Avenue, Santa Maria, RS 97105-900, Brazil; Graduate Program in Biological Sciences: Toxicological Biochemistry, Federal University of Santa Maria, 1000 Roraima Avenue, Santa Maria, RS 97105-900, Brazil; The International Zebrafish Neuroscience Research Consortium (ZNRC), 309 Palmer Court, Slidell, LA 70458, USA. Electronic address:
Article Synopsis
- - Dopamine (DA) is a key neurotransmitter linked to brain function, and its signaling changes are associated with neuropsychiatric disorders like bipolar disorder (BD), which involves mood swings between mania and depression.
- - The drug GBR 12909 is used in research to inhibit DA reuptake, creating experimental conditions that model BD-like behaviors, especially in zebrafish, which are recognized as valuable for studying neurobehavioral changes.
- - The study evaluates GBR 12909's effectiveness in mimicking BD symptoms in zebrafish, emphasizing the role of dopamine transporters and discussing the benefits and challenges of using zebrafish for broader BD research.
Exploration of vanoxerine analogues as antibacterial agents.
J Antibiot (Tokyo)
January 2025
School of Biosciences, University of Birmingham, Birmingham, B15 2TT, UK.
Mycobacterium tuberculosis is a bacterial pathogen, responsible for approximately 1.3 million deaths in 2022 through tuberculosis infections. The complex treatment regimen required to treat tuberculosis and growing rates of drug resistance, necessitates the development of new anti-mycobacterial agents.
View Article and Find Full Text PDFDopamine reuptake and inhibitory mechanisms in human dopamine transporter.
Nature
August 2024
Key Laboratory of Biomacromolecules (CAS), National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
The dopamine transporter has a crucial role in regulation of dopaminergic neurotransmission by uptake of dopamine into neurons and contributes to the abuse potential of psychomotor stimulants. Despite decades of study, the structure, substrate binding, conformational transitions and drug-binding poses of human dopamine transporter remain unknown. Here we report structures of the human dopamine transporter in its apo state, and in complex with the substrate dopamine, the attention deficit hyperactivity disorder drug methylphenidate, and the dopamine-uptake inhibitors GBR12909 and benztropine.
View Article and Find Full Text PDFA novel reuptake inhibitor, IP2015, induces erection by increasing central dopamine and peripheral nitric oxide release.
Br J Pharmacol
August 2024
Department of Biomedicine, Pulmonary and Cardiovascular Pharmacology, Aarhus University, Aarhus, Denmark.
Background And Purpose: An estimated 40% of patients with erectile dysfunction have a poor prognosis for improvement with currently available treatments. The present study investigated whether a newly developed monoamine transport inhibitor, IP2015, improves erectile function.
Experimental Approach: We investigated the effects of IP2015 on monoamine uptake and binding, erectile function in rats and diabetic mice and the effect on corpus cavernosum contractility.
Repurposing the dopamine transporter antagonist vanoxerine to treat colorectal cancer.
Nat Cancer
March 2024
Nash Family Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!